Johnson & Johnson has been awarded a $40 million liability by a Los Angeles jury for allegedly causing ovarian cancer in two women through the use of its talcum powder, a decision that follows a long history of litigation and signals growing investor and regulatory scrutiny over its legacy products.
What Happened in the Verdict
A Los Angeles jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband, finding that Johnson & Johnson’s talcum powder contributed to their ovarian cancer diagnoses.
The decision comes after decades of legal claims tied to the safety of talc-based products, with the company having previously faced similar litigation over mesothelioma and ovarian cancer.
Why This Matters to Investors
While Johnson & Johnson is a global healthcare leader, this verdict underscores a persistent risk in its legacy consumer product portfolio. The company’s exposure to litigation over talc has already led to significant financial and reputational costs.
Investors should consider the long-term implications of such legal outcomes on the company’s earnings stability, product liability insurance costs, and brand trust—especially as the legal landscape continues to evolve.
Historical Context and Legal Trends
Johnson & Johnson has faced multiple high-profile lawsuits over talc-related health claims. In October 2025, a California jury awarded $966 million to the family of a woman who died of mesothelioma, claiming the powder was contaminated with asbestos.
The company has historically argued that talc is safe and does not contain asbestos. However, scientific studies have shown mixed results, with some research suggesting a possible link between talc use and ovarian cancer.
Johnson & Johnson stopped selling talc-based products globally in 2023, replacing them with cornstarch in most of North America in 2020 following declining sales and growing consumer skepticism.
Company Response and Legal Strategy
Johnson & Johnson has stated it will appeal the verdict, asserting it won “16 of the 17 ovarian cancer cases it previously tried” and that the jury’s findings are “irreconcilable with decades of independent scientific evaluations.”
Worldwide vice president of litigation, Erik Haas, emphasized that talc is safe and does not cause cancer, citing scientific consensus and internal testing.
However, the appeal process could extend into 2026, and any future settlements may further strain the company’s balance sheet.
Broader Market and Regulatory Implications
This verdict is not isolated. In April 2025, a U.S. bankruptcy court judge denied Johnson & Johnson’s plan to pay $9 billion to settle all talc-related gynecological cancer claims, highlighting the difficulty of achieving a broad settlement.
Regulators and investors are increasingly watching for how companies manage product liability risks, especially in consumer goods with long shelf lives and widespread use.
Investor Outlook and Risk Assessment
- Product Liability Risk: Johnson & Johnson remains exposed to litigation over legacy products, which could result in future verdicts or settlements.
- Reputational Risk: Consumer trust in the brand has eroded, particularly among women who use personal care products.
- Financial Risk: The company may face rising insurance premiums and legal expenses, impacting future profitability.
- Strategic Shift: The move to cornstarch signals a strategic pivot, but long-term brand loyalty may be challenged by consumer perception.
The verdict is a pivotal moment in Johnson & Johnson’s history, reinforcing the need for companies to proactively manage product safety and consumer trust. For investors, it serves as a cautionary tale about the long-term risks of legacy products in a litigious and informed market.
For those holding shares in Johnson & Johnson, this development should be viewed as part of a broader pattern of legal and reputational risk exposure. While the company remains a strong performer in pharmaceuticals and medical devices, its consumer products division continues to face significant scrutiny.
Stay updated with our daily financial analysis for the latest developments in corporate liability, litigation, and investor risk.
